Browsing by Author "Haytoglu, Zeliha"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Bocavirus Viremia and Hepatitis in an Immunocompetent Child
    (2017) Canan, Oguz; Haytoglu, Zeliha; 0000-0003-0614-4497; 28443581; AAI-9386-2021
    Background: So far, many studies have shown that Human Bocavirus (HBoV) is the main pathogen of the respiratory tract. Until now, there is no study that proves the association between HBoV and hepatitis. HBoV viremia/DNAemia has been associated closely with acute primary infection and moderate-to-severe illness but, more detailed clinical data about HBoV dissemination are still unavailable. Case Report: Here we report a 2-years-5-months-old girl suffering from respiratory distress and heptitis followed in our intensive care unit. HBoV was detected in our patients nose and throat swabs concurrent with whole blood sample by positive polymerase chain reactions. After a through investigation no causative agent other than HBoV viremia was found. Conclusion: Human Bocavirus viremia with high viral loads may be associated with hepatitis.
  • No Thumbnail Available
    Item
    Secondary Hemophagocytic Lymphohistiocytosis: Do We Really Need Chemotherapeutics for All Patients?
    (2017) Haytoglu, Zeliha; Yazici, Nalan; Erbay, Ayse; https://orcid.org/0000-0002-8371-5137; 28060133; AAM-5138-2021
    Because of the acute and life-threatening course of the hemophagocytic lymphohistiocytosis (HLH) syndrome, International Histiocyte Society guidelines recommend chemoimmune therapy for the treatment of both primary and secondary HLH (sHLH). To manage children with sHLH, instead of HLH-2004 protocol we considered less immunosuppressive/cytotoxic approach. We assessed 12 children who fulfilled the diagnostic criteria for sHLH between January 2009 and March 2015. Multivariate Cox regression analysis showed that ferritin levels (hazard ratio= 1.02, P = 0.006), pediatric logistic organ dysfunction scores (hazard ratio = 1.01, P = 0.001) were the predictors of the survival. The hospital survival was 83% for patients with sHLH who were treated with less immunosuppressive therapy. In conclusion initiation of HLH-specific therapy for the patients with hyperferritinemia-associated sHLH should be delayed while awaiting resolution of systemic inflammation with less immunosuppressive therapy.